Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

Norah A. Terrault*, Stefan Zeuzem, Adrian M. Di Bisceglie, Joseph K. Lim, Paul J. Pockros, Lynn M. Frazier, Alexander Kuo, Anna S. Lok, Mitchell L. Shiffman, Ziv Ben Ari, Lucy Akushevich, Monika Vainorius, Mark S. Sulkowski, Michael W. Fried, David R. Nelson, David R. Nelson, Michael W. Fried

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

176 Scopus citations

Abstract

Background & Aims The combination of ledipasvir and sofosbuvir has been approved for treatment of genotype 1 hepatitis C virus (HCV) infection, including an 8-week regimen for treatment-naïve patients without cirrhosis and a baseline level of HCV RNA <6 million IU/mL. We analyzed data from a multicenter, prospective, observational study to determine real-world sustained virologic responses 12 weeks after treatment (SVR12) with regimens containing ledipasvir and sofosbuvir and identify factors associated with treatment failure. Methods We collected data from 2099 participants in the HCV-TARGET study with complete virologic data (per-protocol population). We analyzed data from 1788 patients receiving ledipasvir-sofosbuvir (282 for 8 weeks, 910 for 12 weeks, 510 for 24 weeks, and 86 for a different duration) and 311 receiving ledipasvir-sofosbuvir plus ribavirin (212 for 12 weeks and 81 for 24 weeks, 18 for other duration) to estimate SVR12 (with 95% confidence interval [CI]), and logistic regression methods to identify factors that predicted an SVR12. Results The overall study population was 25% black, 66% with HCV genotype 1A infection, 41% with cirrhosis, 50% treatment-experienced, and 30% receiving proton pump inhibitors at start of treatment. In the per-protocol population, SVR12s were achieved by 96% of patients receiving ledipasvir-sofosbuvir for 8 weeks (95% CI, 93%−98%), 97% receiving the drugs for 12 weeks (95% CI, 96%−98%), and 95% receiving the drugs for 24 weeks (95% CI, 93%−97%). Among patients also receiving ribavirin, SVR12 was achieved by 97% of the patients receiving the drugs for 12 weeks (95% CI, 94%−99%) and 95% receiving the drugs for 24 weeks (95% CI, 88%−99%). Of the 586 patients who qualified for 8 weeks of treatment, only 255 (44%) received the drugs for 8 weeks. The rate of SVR12 among those who qualified for and received 8 weeks of therapy was similar in those who qualified for 8 weeks but received 12 weeks therapy (96%; 95% CI, 92%−99% vs 98%; 95% CI, 95%−99%). Factors that predicted SVR12 were higher albumin (≥3.5 g/dL), lower total bilirubin (≤1.2 g/dL), absence of cirrhosis, and absence of proton pump inhibitor use. Conclusions Regimens containing ledipasvir and sofosbuvir are highly effective for a broad spectrum of patients with HCV genotype 1 infection treated in different clinical practice settings. Expanded use of 8-week treatment regimens for eligible patients is supported by these real-world results. Modification of proton pump inhibitor use may increase rates of SVR. ClinicalTrials.gov no. NCT01474811.

Original languageEnglish
Pages (from-to)1131-1140.e5
JournalGastroenterology
Volume151
Issue number6
DOIs
StatePublished - 1 Dec 2016
Externally publishedYes

Funding

FundersFunder number
Genentech/Roche
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney DiseasesK24DK066144
National Institute of Diabetes and Digestive and Kidney Diseases
Bristol-Myers Squibb
GlaxoSmithKline
Merck
Gilead Sciences
National Center for Advancing Translational SciencesUL1TR001427
National Center for Advancing Translational Sciences
AbbVie
University of North Carolina at Chapel Hill
Janssen Pharmaceuticals
University of South Florida

    Keywords

    • Antiviral
    • DAA
    • NS5A Inhibitor
    • NS5B Inhibitor

    Fingerprint

    Dive into the research topics of 'Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response'. Together they form a unique fingerprint.

    Cite this